Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2023 Annual General Meeting
    • 2023 Special Meeting
    • FAQ
  • Analyst Coverage
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR+
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jun 08, 2022 9:00am EDT

Lexaria Grants License to AnodGen Bioceuticals

Jun 06, 2022 9:15am EDT

Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA

Jun 03, 2022 2:00am EDT

Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market

Jun 02, 2022 9:05am EDT

Lexaria Grants License to Valcon Medical for the European Market

Jun 01, 2022 9:00am EDT

Lexaria Announces 2022 Annual Meeting Results

May 26, 2022 8:30am EDT

Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space

May 25, 2022 8:30am EDT

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space

Apr 21, 2022 9:05am EDT

Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs

Apr 19, 2022 9:05am EDT

Lexaria Commences Multi-Week Human Clinical Hypertension Study

Apr 14, 2022 8:45am EDT

Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Canadian Operations
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

US Operations
2226 W. Northern Avenue
Phoenix, AZ 85021

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2023 All rights reserved.

Back to the top